[Use of polyplatillen in chemotherapy of advanced pancreatic cancer].

The results of Poliplatillen clinical application in 108 patients with advanced pancreatic cancer were analyzed. The use of Poliplatillen in adjuvant regimen improves the long-term results of treatment. The mean survival time was increased on 2.

[Improvement of the quality of life in patients with non-operable pancreatic cancer treated with polyplatillen].

The authors summarize in the article experience of a new anticancer drug Polyplatillen use in the chemotherapy of advanced pancreatic cancer. Polyplatillen use in the palliative chemotherapy in the patients with advanced pancreatic cancer permits to realize a control of pain and stabilize an ECOG status. Tendency to the improvement of total survival during an early period was registered in the group of patients with advanced pancreatic cancer who were treated with Polyplatillen.

[The survival indices of patients with stage IV gastric cancer treated by polyplatilen].

The survival indices of patients suffering gastric cancer stage IV in application of cytostatic preparation polyplatilen were studied up. The most expedient mode of treatment was suggested the conduction of no less than 2 courses of monochemotherapy. As a result, one year had survived (22.

[Chemotherapy of the small cell lung cancer using polyplatillen].

The experience of application of a new antitumoral platinum--containing preparation--polyplatyllen--in the treatment of the small cell pulmonary cancer was summarized. It was established, that the security profile of polyplatyllen is more favourable and efficacy in the treatment of the extended small cell pulmonary cancer is higher, than those of the standard scheme of treatment using cisplatinum and etoposide. The quality of life of the patients, while application of polyplatyllen, is more stable, than in application of the combined prescription of cisplatinum and etoposide.

[Results of palliative chemoradiotherapy of advanced small cell lung cancer using polyplatillen].

In the article authors summarize the experience of new anticancer drug polyplatillen usud in the chemoradiotherapy of small cell lung cancer. Polyplatillen improves the tumor response, general and relapse-free survival of advanced small cell lung cancer treatment in comparance with traditional VEC scheme.